More patients achieved composite reductions of ≥1% HbA1c, ≥5% body weight and ≥5 mmHg systolic blood pressure with semaglutide versus comparators (SUSTAIN 1–5, 7)

Related Event
ABCD Autumn Meeting 2018

File(s)

More patients achieved composite reductions of ≥1% HbA1c, ≥5% body weight and ≥5 mmHg systolic blood pressure with semaglutide v

Discipline

Diabetes

Resource taxonomy

Event resources Posters

Clinical taxonomy

Obesity Treatments for diabetes

Listing status